Evidence map›Paper›PMID 42162412›Full record

ArticleEJNMMI radiopharmacy and chemistry2026

CXCR4-targeted PET imaging of glioblastoma using [

Piyapan Suwattananuruk, Stine Figenschau, Angel Moldes-Anaya, Efat Muhammad Arshad, Rodrigo Berzaghi, Lars Kjelsberg Pedersen, Rune Sundset, Pornchai Rojsitthisak, Opa Vajragupta, Mathias Kranz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Piyapan SuwattananurukPET Imaging Center, University Hospital of North Norway, Hansine Hansens Vei 82, 9019, Tromsø, Norway.ORCID http://orcid.org/0009-0008-3747-1750
Stine FigenschauPET Imaging Center, University Hospital of North Norway, Hansine Hansens Vei 82, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0002-3714-9998
Angel Moldes-AnayaPET Imaging Center, University Hospital of North Norway, Hansine Hansens Vei 82, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0002-2338-5850
Efat Muhammad ArshadDepartment of Medical Biology, Tumor Biology Research Group, UiT The Arctic University of Norway, Hansine Hansens Vei 82, 9037, Tromsø, Norway.ORCID http://orcid.org/0000-0003-1276-0392
Rodrigo BerzaghiDepartment of Clinical Medicine, UiT The Arctic University of Norway, Hansine Hansens Vei 82, 9037, Tromsø, Norway.
Lars Kjelsberg PedersenDepartment of Neurosurgery, Ophthalmology and Otorhinolaryngology, University Hospital of North Norway, Hansine Hansens Vei 82, 9019, Tromsø, Norway.
Rune SundsetPET Imaging Center, University Hospital of North Norway, Hansine Hansens Vei 82, 9019, Tromsø, Norway.ORCID http://orcid.org/0000-0002-0072-2076
Pornchai RojsitthisakDepartment of Food and Pharmaceutical Chemistry and Center of Excellence in Natural Products for Ageing and Chronic Diseases, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Pathumwan, Bangkok, 10330, Thailand.ORCID http://orcid.org/0000-0003-1391-6993
Opa VajraguptaDepartment of Food and Pharmaceutical Chemistry and Center of Excellence in Natural Products for Ageing and Chronic Diseases, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Phayathai Road, Pathumwan, Bangkok, 10330, Thailand. opa.vaj@mahidol.ac.th.ORCID http://orcid.org/0000-0003-3313-0621
Mathias KranzPET Imaging Center, University Hospital of North Norway, Hansine Hansens Vei 82, 9019, Tromsø, Norway. mathias.kranz@uit.no.ORCID http://orcid.org/0000-0002-5641-7396

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGlioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and limited treatment options. Chemokine receptor type 4 (CXCR4) plays a key role in GBM invasion and therapy resistance, making it an attractive target for molecular imaging and theranostics. We developed [

resultsIn mice bearing orthotopic GL261 GBM, dynamic PET/MRI, receptor blocking studies, and kinetic modeling demonstrated a specific binding component and high tumor-to-background contrast. [

conclusionsWhen compared with reported data for [

Indexed as

Chemokine receptor PET imagingCXCR4GlioblastomaPET pharmacokinetic modelingPharmacokineticPredictive dosimetryTumor microenvironmentWhole-body dosimetry

Identifiers

PMID42162412
PMCPMC13365296

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.